Australia markets closed

TC Biopharm (Holdings) Plc (TCBP)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
1.1300-0.0100 (-0.88%)
At close: 04:00PM EDT
1.1201 -0.01 (-0.88%)
After hours: 07:59PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 5.59M
Enterprise value 4.75M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.51
Price/book (mrq)1.64
Enterprise value/revenue 1.83
Enterprise value/EBITDA -0.17

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-99.30%
S&P500 52-week change 326.49%
52-week high 3200.0000
52-week low 30.8500
50-day moving average 31.4696
200-day moving average 335.0246

Share statistics

Avg vol (3-month) 34.86M
Avg vol (10-day) 35.1M
Shares outstanding 54.95M
Implied shares outstanding 63.2M
Float 898.78M
% held by insiders 10.02%
% held by institutions 10.30%
Shares short (30 Apr 2024) 4187.71k
Short ratio (30 Apr 2024) 40.04
Short % of float (30 Apr 2024) 46.91%
Short % of shares outstanding (30 Apr 2024) 45.87%
Shares short (prior month 28 Mar 2024) 4204.48k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 315 Dec 2023

Financial highlights

Currency in GBP.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-108.91%
Return on equity (ttm)-556.68%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -12.92M
Net income avi to common (ttm)-8.59M
Diluted EPS (ttm)-24.3600
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)980.96k
Total cash per share (mrq)0.01
Total debt (mrq)1.73M
Total debt/equity (mrq)159.94%
Current ratio (mrq)0.88
Book value per share (mrq)1.05

Cash flow statement

Operating cash flow (ttm)-10.04M
Levered free cash flow (ttm)-6.85M